ClinicalTrials.gg
Status unknownNCT03363178Updated Dec 18, 2017

Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults

A Phase 1 interventional study of GC3107 in Tuberculosis, sponsored by Green Cross Corporation. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-18.

Sponsored by Green Cross Corporation · Phase 1, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
19 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 46 studies in Tuberculosis with a site in Korea, Republic of — 4 open to participants now, 4 under way, 1 of them phase 3. Tuberculosis · Korea, Republic of.

Planned enrollment
19th of 24
20 · median 104
Started
2017
with 2 others
Phase 1
3 of 46
none open now
Registered
32nd of 46
by date
Lead sponsor
2 of 46
Green Cross Corporation

Among the 46 studies in Tuberculosis with a site in Korea, Republic of, this one is the 19th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2017, is one of 3 in phase 1, and was the 32nd registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

4 of the 46 studies in Tuberculosis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 19 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Tuberculosis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally.

Read the detailed description

Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally. Tuberculin Skin Test(TST) will be conducted after 84+7 days after IP injection and TST result will be read in 48\~72 hours.

03

Conditions studied

  • Tuberculosis

Browse trials for

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 19-64 years old
  • form has been signed and dated
  • Able to comply with the requirements of the study
  • Female subjects who have negative results in Urine hCG test at screening, or menopausal women.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have positive results(;induration diameter over 5mm) in Tuberculin Skin Test(TST) at screening
  • Subjects who shown abnormal results(including inactive tuberculosis) on Chest X-ray at screening
  • Subjects who received a vaccination(including ) within 28 days before enrollment
  • Subjects who are on antituberculosis drugs
  • subjects with immunodeficiency disease or subjects receiving immunosuppressive or immunomodulating therapy
  • Subjects with severe chronic disease who are considered by investigator to be ineligible for the study
  • Pregant or lactating women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    GC3107

    BCG Vaccine, 0.1mL

    Biological: GC3107

Interventions

  • BiologicalGC3107

    BCG Vaccine, 0.1mL

06

What researchers measure

Primary outcomes

  1. Adverse Event

    Solicited/Unsolicited Adverse Event

    Time frame: for 7 days from Day0/during study period

Secondary outcomes

  1. Whether the maximum Induration diameter greater than 5mm after TST.

    Induration diameter measured in the direction perpendicular to the arm.

    Time frame: Day0+84days

  2. Whether the maximum Erythema/Redness diameter greater than 5mm after TST.

    Erythema/Redness diameter measured in the direction perpendicular to the arm.

    Time frame: Day0+84days

  3. Maximum diameter of Induration after TST.

    Induration diameter measured in the direction perpendicular to the arm.

    Time frame: Day0+84days

  4. Maximum diameter of Erythema/Redness after TST.

    Erythema/Redness diameter measured in the direction perpendicular to the arm.

    Time frame: Day0+84days

  5. Maximum diameter variation of Induration after TST.

    Induration diameter measured in the direction perpendicular to the arm.

    Time frame: Day0+84days

  6. Maximum diameter variation of Erythema/Redness after TST.

    Erythema/Redness diameter measured in the direction perpendicular to the arm.

    Time frame: Day0+84days

07

Study locations

1 of 1 sites recruiting
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
    Recruiting
    • Woo Joo Kim, M.D. Ph.D. · Contactwjkim@korea.ac.kr
    • Woo Joo Kim, M.D. Ph.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Mar 2018, 3 months after the start.

Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 6, 2017
StartActual
Dec 14, 2017
Primary completionEst.
Mar 31, 2018
CompletionEst.
Mar 31, 2018
Last update
Dec 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03363178
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Dec 14, 2017
Primary completion
Mar 31, 2018 (estimated)
Completion
Mar 31, 2018 (estimated)
Last update
Dec 18, 2017

Study contacts

Yoonjung Nam, Pharm.D
Contact
clairenam@greencross.com
+81-260-9143
Woo Joo Kim, M.D, Ph.D
principal investigator · Korea University Guro Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion